Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


International regulators make dementia plans

This article was originally published in Scrip

Executive Summary

The conclusions of a workshop involving 10 medicines regulators held in Geneva in November 2014 have been published by the UK's MHRA, which noted that the meeting was the first time the regulators had met globally to discuss dementia. With the aim of providing a supportive environment for drug development in this area of high unmet need, six areas were identified in which regulators and other clinical and scientific experts and analysts will collaborate to find a solution to the problem. These included analysing the factors behind the termination of development programs over the past 10-15 years; considering how to make clinical trials more efficient; composite endpoints and benefit-risk balance including exploring expedited approval procedures. Participants in the initial workshop included the European Medicines Agency and regulators from several countries including the US, Japan, Germany, Italy, Denmark, the UK, the Netherlands, Canada and Switzerland. The meeting was convened by the UK government, which is also supporting the World Health Organization's first ministerial conference on global action against dementia in Geneva on 16-17 March.

You may also be interested in...

Re-Wiring US FDA’s Regulatory Thinking

The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.

Congressional Democrats Press US FDA For Transparency In Review Of COVID-19 Vaccines

FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.

Flutter Over Biocon’s Repurposed Psoriasis Drug For COVID-19 In India

Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts